16578744517_ed4293d3e7_z

Patient dies after receiving faecal transplant

pharmafile | June 17, 2019 | News story | Sales and Marketing Adverse Event, E.Coli. AMR, FDA, faecal transplant, pharma 

A person has died after experiencing an adverse event related to a faecal transplant.

The FDA has warned that two immunocompromised patients developed invasive infections caused by multi drug resistant bacteria, after receiving a faecal transplant.

The patients were infected with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E.coli) after receiving faecal microbiota for transplantation (FMT) from the same donor.

The donor stool and resulting FMT used in these two individuals were not tested for ESBL-producing gram-negative organisms prior to use.

Both patients then developed antibiotic resistant E.Coli infections. One of the patients subsequently died.

FMT is an experimental treatment Clostridium difficile, a bacterial infection which causes severe diarrhoea.

“While we support this area of scientific discovery, it’s important to note that FMT does not come without risk,” said Dr Peter Marks, director of FDA’s Center for Biologics Evaluation and Research.

“We’ve become aware of infections with multi-drug resistant organisms after patients received investigational FMT, including one patient death. We therefore want to alert all health care professionals who administer FMT about this potential serious risk so they can inform their patients.”

Louis Goss

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

GSK’s meningococcal vaccine candidate accepted for FDA review

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan …

Latest content